[1]  Gao Hui(高辉), Zhong Jing-fen(钟静芬), Shi Hui-lin(时惠麟). Graphical synthetic routes of clevidipine butyrate(丁酸氯维地平合成路线图解)
[J]. Chinese J Pharmaceutical(中国医药工业杂志), 2009, 40(10): 791-793.

[2]  Andersson K H,  Nordlander M, Westerlund R C, et al. ShortActing Dihydropyridines: WO9512578A1[P]. 1995-05-11.

[3]  Sun Hua-jun(孙华君), Huang Lu(黄璐), Yang Bo(杨波), et al. Preparation of Dihydropyridines Compounds(一种二氢吡啶类化合物的制备方法): 中国，CN101638379A[P]. 2009-08-21.

[4]  Yang Bo(杨波), Sun Hua-jun(孙华君), Huang Lu(黄璐), et al. Crystal form of clevidipine butyrate(丁酸氯维地平的晶型): 中国, CN101768105A[P]. 2010-01-19.

[5]  Aronson S, Dyke C M, Stierer K A, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients[J]. Anesthesia & Analgesia, 2008, 107(4): 1 110-1 121. 

[6]  Pollack C V,  Varon J,  Garrison N A, et al. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension[J]. Annals of Emergency Medicine, 2009, 53(3): 329-338.

[7]  Ning Yong-cheng(宁永成). Structural Identification of Organic Compounds and Organic Spectroscopy(有机化合物结构鉴定与有机波谱学)
[M]. Beijing(北京): Science Press(科学出版社), 2000.